Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
With this research investigators hope to begin to understand how rTMS can improve posttraumatic stress disorder (PTSD) symptoms. TMS improves PTSD through two interrelated mechanisms: change in brain limbic system function and change in systemic inflammatory activation. Participants who decide to join this study, will receive ten rTMS treatments. All participants will undergo a 40-minute rTMS procedure with a member of the study team 10 times over 2-4 weeks. Participants will undergo fMRI scans of the head in order to help researchers better understand potential effects of rTMS on brain activity. In addition, participants will be asked to give two breath and blood samples to look for signs of general inflammation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants receiving open label trial of TMS | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Transcranial Magnetic Stimulation | Device | 10 sessions of low frequency rTMS (1Hz) applied to the right dorsolateral prefrontal cortex. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Frequency and intensity of PTSD symptoms as assessed by the CAPS-5 | The CAPS is a clinician-administered scale of PTSD symptoms, which queries the frequency and intensity of symptoms of PTSD | From enrollment to the end of treatment at 3 months |
| 20 item self-report of PTSD symptoms assessed by PCL-5 | It asks participants to rate the severity of each of the 20 symptoms of PTSD in DSM-5 | From enrollment to the end of treatment at 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| A quick self-reported and self administered inventory of depressive symptoms (QIDS-16-SR) | This is a self-reported, self- administered scale of depressive symptoms. | From the baseline to the end of the study at 3 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Bradley V Watts, MD, MPH | Contact | 802-295-9363 | 5235 | bradley.watts@va.gov |
| Julian Sewall | Contact | 603-266-7140 | julian.sewall@va.gov |
| Name | Affiliation | Role |
|---|---|---|
| Bradley Watts | US Department of Veterans Affairs | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| White River Junction VA Hospital | Recruiting | White River Junction | Vermont | 05001 | United States |
Not provided
| ID | Term |
|---|---|
| D003130 | Combat Disorders |
| ID | Term |
|---|---|
| D040921 | Stress Disorders, Traumatic |
| D000068099 | Trauma and Stressor Related Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D050781 | Transcranial Magnetic Stimulation |
| ID | Term |
|---|---|
| D055909 | Magnetic Field Therapy |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided